David E. Cohen Sells 600 Shares of Dermira Inc (DERM) Stock

Dermira Inc (NASDAQ:DERM) Director David E. Cohen sold 600 shares of Dermira stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $25.49, for a total transaction of $15,294.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Shares of Dermira Inc (NASDAQ DERM) traded up $0.09 during trading on Thursday, hitting $24.79. 383,080 shares of the stock were exchanged, compared to its average volume of 426,451. The company has a current ratio of 4.68, a quick ratio of 4.68 and a debt-to-equity ratio of 1.40. Dermira Inc has a 52-week low of $21.35 and a 52-week high of $38.75.

Several institutional investors have recently modified their holdings of the company. AXA grew its position in shares of Dermira by 41.5% in the 3rd quarter. AXA now owns 300,333 shares of the biopharmaceutical company’s stock worth $8,109,000 after buying an additional 88,079 shares during the last quarter. GSA Capital Partners LLP purchased a new position in shares of Dermira in the 3rd quarter worth approximately $696,000. Point72 Asset Management L.P. grew its position in shares of Dermira by 621.8% in the 3rd quarter. Point72 Asset Management L.P. now owns 712,904 shares of the biopharmaceutical company’s stock worth $19,248,000 after buying an additional 614,138 shares during the last quarter. Alyeska Investment Group L.P. grew its position in shares of Dermira by 1.8% in the 3rd quarter. Alyeska Investment Group L.P. now owns 351,059 shares of the biopharmaceutical company’s stock worth $9,479,000 after buying an additional 6,270 shares during the last quarter. Finally, Platinum Investment Management Ltd. grew its position in shares of Dermira by 60.1% in the 3rd quarter. Platinum Investment Management Ltd. now owns 92,400 shares of the biopharmaceutical company’s stock worth $2,494,000 after buying an additional 34,700 shares during the last quarter. 99.54% of the stock is currently owned by hedge funds and other institutional investors.

A number of research analysts have commented on DERM shares. Cantor Fitzgerald reissued a “buy” rating and set a $45.00 target price on shares of Dermira in a research report on Monday, November 6th. Zacks Investment Research downgraded shares of Dermira from a “hold” rating to a “sell” rating in a research report on Thursday, November 9th. Leerink Swann reissued an “outperform” rating and set a $41.00 target price (down previously from $47.00) on shares of Dermira in a research report on Tuesday, November 7th. Mizuho reissued a “buy” rating and set a $43.00 target price (up previously from $40.00) on shares of Dermira in a research report on Thursday, September 7th. Finally, Needham & Company LLC reissued a “buy” rating and set a $43.00 target price (down previously from $46.00) on shares of Dermira in a research report on Tuesday, November 7th. Four analysts have rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $43.33.

COPYRIGHT VIOLATION NOTICE: “David E. Cohen Sells 600 Shares of Dermira Inc (DERM) Stock” was originally posted by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3080608/david-e-cohen-sells-600-shares-of-dermira-inc-derm-stock.html.

Dermira Company Profile

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Insider Buying and Selling by Quarter for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.